Insider Trading Activity Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) – Director Bought 20,400 shares of Stock

Insider Trading Activity For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Douglas L Braunstein , Director of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) reportedly Bought 20,400 shares of the company’s stock at an average price of 49.07 for a total transaction amount of $1,001,028.00 SEC Form

Insider Trading History For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

On 2/18/2014 Jay Moorin, Director, bought 333,333 with an average share price of $15.00 per share and the total transaction amounting to $4,999,995.00.View SEC Filing

On 6/16/2015 Steven L Krill, Insider, sold 9,980 with an average share price of $81.60 per share and the total transaction amounting to $814,368.00.View SEC Filing

On 7/1/2015 Scott Tarriff, CEO, sold 135,710 with an average share price of $46.34 per share and the total transaction amounting to $6,288,801.40.View SEC Filing

On 9/1/2015 Scott Tarriff, CEO, sold 16,245 with an average share price of $76.95 per share and the total transaction amounting to $1,250,052.75.View SEC Filing

On 10/1/2015 Scott Tarriff, CEO, sold 17,878 with an average share price of $69.92 per share and the total transaction amounting to $1,250,029.76.View SEC Filing

On 11/2/2015 Scott Tarriff, CEO, sold 19,339 with an average share price of $64.63 per share and the total transaction amounting to $1,249,879.57.View SEC Filing

On 12/1/2015 Scott Tarriff, CEO, sold 14,050 with an average share price of $88.93 per share and the total transaction amounting to $1,249,466.50.View SEC Filing

Analyst Ratings For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
These are 1 Sell Rating, 3 Buy Ratings .
The current consensus rating for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is Buy (Score: 2.50) with a consensus target price of $73.25 , a potential (31.65% upside)

Analyst Ratings History For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

• On 11/2/2016 William Blair Boost Price Target of rating Outperform with a price target of $83.00 to $97.00
• On 7/27/2017 Mizuho Lower Price Target of rating Underperform to Underperform with a price target of $57.00 to $40.00
• On 7/27/2017 Royal Bank Of Canada Lower Price Target of rating Outperform to Outperform with a price target of $94.00 to $81.00
• On 8/9/2017 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $75.00

Recent Trading Activity for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Shares of Eagle Pharmaceuticals, Inc. closed the previous trading session at 55.64 up +5.57 11.12% with 648,756 shares trading hands.